Neoantigen Identification: A Microfluidics-Assisted Workflow for Fine Needle Biopsies

Tumor antigens showcased by MHC molecules on cell surfaces are targets for T cells. The exploration of these antigens, termed immunopeptidomics, has greatly impacted the progress of cancer immunotherapies. To ensure optimal results, these therapies must tailor to the individual genetic vulnerabilities of each patient's tumor. However, conventional methods require a significant starting material of over 50 million cells, rendering them impractical for fine needle-aspirated biopsies, which typically yield 7,000 to 500,000 cells.

In this on-demand webinar, Dr. Joseph Ndika, Senior Scientist at Valo Therapeutics, presents a methodology utilizing Valo Therapeutics' groundbreaking microfluidics-based immunoaffinity platform (PeptiCHIPTM) alongside Bruker's ultra-high sensitivity mass spectrometer timsTOF Ultra. This combined approach aims to identify tumor-specific HLA Class I antigens even from samples as small as 10,000 cells.

Gain insights into:

• Best practices for the miniaturized enrichment of MHC-bound peptides
• How to conduct HLA class I immunopeptidomics on a timsTOF Ultra
• The significance of immunogenic prioritization of tumor antigens